<DOC>
	<DOCNO>NCT02611505</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics , safety , tolerability intranasally administer esketamine participant vary stage hepatic impairment healthy participant .</brief_summary>
	<brief_title>A Study Assess Effects Hepatic Impairment Pharmacokinetics , Safety , Tolerability Intranasally Administered Esketamine</brief_title>
	<detailed_description>This parallel group , single-center , single-dose , open-label ( people know identity intervention ) , study ass pharmacokinetics safety single 28 milligram ( mg ) dose esketamine participant vary stage hepatic impairment healthy participant . The participant assign 1 3 group ( 8 participant per group ) base hepatic impairment classify Screening . Cohort 1 ( participant moderate hepatic impairment ) , Cohort 2 ( participant mild hepatic impairment ) , Cohort 3 ( participant normal hepatic function evidence liver damage ) . Participants self-administer single dose intranasal Esketamine 28 mg . The total duration study Screening Follow-up , approximately 34 38 day . Blood urine sample assessment Esketamine pharmacokinetics collect 60 hour study drug administration . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Cohorts 1 , 2 3 ( All participant ) : Body mass index ( BMI ) 18 34 kilogram ( kg ) /meter square ( [ ] ^2 ) ( inclusive ) , body weight less 50 kilogram ( kg ) Creatinine clearance great equal ( &gt; = ) 60 milliliter per minute ( mL/min ) base CockcroftGault equation Signed informed consent document indicate understand purpose procedure require study willing participate study Cohorts 1 2 ( Participants Hepatic impairment ) : A total ChildPugh score 5 6 participant mild impairment 7 9 ( inclusive ) participant moderate impairment Participants must stable hepatic function consistent classification ( mild moderate hepatic impairment ) Screening Day 1 Cohorts 1 , 2 3 ( All participant ) : Participants Asian origin Diagnosed current previous psychotic major depressive disorder ( MDD ) psychosis , bipolar relate disorder , intellectual disability , borderline personality disorder , antisocial personality disorder Cohorts 1 2 ( Participants Hepatic impairment ) : History hepatopulmonary syndrome , hydrothorax hepatorenal syndrome Positive test alcohol drug abuse per local standard practice Cohorts 3 ( Healthy participant ) : Clinically significant medical illness Clinically significant abnormal value hematology , clinical chemistry , urinalysis Screening admission study center ( Day 1 ) deem appropriate investigator Positive test human immunodeficiency virus ( HIV ) 1 2 antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Esketamine</keyword>
	<keyword>Hepatic Impairment</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>